family with sequence similarity 86, member A pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM86MP profile across patient tissues and cancer cell-line models. FAM86MP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, FAM86MP is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FAM86MP RNA expression shows 11,517 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, THCA, and TGCT as cancer lineages where FAM86MP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86MP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86MP survival associations across molecular data types. FAM86MP RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86MP RNA expression–survival associations across cancer types. High FAM86MP expression shows unfavorable associations in DLBC, ACC, THCA and LIHC, but favorable associations in THYM and STAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify DLBC as the clearest survival context for FAM86MP RNA expression.
This table summarizes FAM86MP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86MP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86MP shows lower tumor expression in THCA and KIRC and higher tumor expression in UCEC, BRCA, COAD and READ. The THCA box plot shows higher FAM86MP RNA expression in normal versus tumor tissue (log2 FC = −0.285, t-test p < 0.001).
This table shows molecular features associated with FAM86MP in patient tissues and cancer cell lines. In patient samples, FAM86MP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
